Evidence map›Paper›PMID 19047046›Full record

ArticleThe Journal of biological chemistry2009

Role of Src signal transduction pathways in scatter factor-mediated cellular protection.

Saijun Fan, Qinghui Meng, John J Laterra, Eliot M Rosen

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. TheScience signaling · 2022
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Saijun FanDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Qinghui Meng
John J Laterra
Eliot M Rosen
Georgetown University Medical Center · USGeorgetown University · USJohns Hopkins Medicine · US

Funding

Mechanisms of Chemo/Radioresistance in Human GliomasR01NS043987 · NINDS · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI LATERRA, JOHN J, ROSEN, ELIOT M. · 2003 to 2012
$4.9M
BIOCHEMISTRY OF BRAIN TUMOR MICROVESSEL DEVELOPMENTR01NS032148 · NINDS · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI LATERRA, JOHN J · 1995 to 2007
$3.0M
PROTECTION AGAINST APOPTOSIS BY SCATTER FACTORR01ES009169 · NIEHS · LONG ISLAND JEWISH MEDICAL CENTER · PI ROSEN, ELIOT M · 1998 to 2006
$2.3M
NIEHS NIH HHS R01-ES09169NINDS NIH HHS R01 NS032148NINDS NIH HHS R01-NS43987
6 · The paper itself

Abstract

Scatter factor (SF) (hepatocyte growth factor) is a pleiotrophic cytokine that accumulates in tumors, where it may induce invasion, angiogenesis, and chemoresistance. We have studied the mechanisms by which SF and its receptor (c-Met) protect cells against the DNA-damaging agent adriamycin (ADR) as a model for chemoresistance of SF/c-Met-overexpressing tumors. Previous studies identified a phosphatidylinositol 3-kinase/c-Akt/Pak1/NF-kappaB cell survival pathway in DU-145 prostate cancer and Madin-Darby canine kidney epithelial cells. Here we studied Src signaling pathways involved in SF cell protection. Src enhanced basal and SF stimulated NF-kappaB activity and SF protection against ADR, in a manner dependent upon its kinase and Src homology 3 domains; and endogenous Src was required for SF stimulation of NF-kappaB activity and cell protection. The ability of Src to enhance SF stimulation of NF-kappaB activity was due, in part, to its ability to stimulate Akt and IkappaB kinase activity; and Src-mediated stimulation of NF-kappaB was due, in part, to a Rac1/MKK3/6/p38 pathway and was Akt-dependent. SF caused the activation of Src and the Rac1 effector Pak1. Furthermore, SF induced activating phosphorylations of MKK3, MKK6, and p38 within the c-Met signalsome in an Src-dependent manner. The NF-kappaB-inducing kinase was found to act downstream of TAK1 (transforming growth factor-beta-activated kinase 1) as a mediator of SF- and Src-stimulated NF-kappaB activity. Finally, the Src/Rac1/MKK3/6/p38 and Src/TAK1/NF-kappaB-inducing kinase pathways exhibited cross-talk at the level of MKK3. These findings delineate some novel signaling pathways for SF-mediated resistance to ADR.

Indexed as

Drug Resistance, NeoplasmMAP Kinase Signaling SystemAnimalsAntibiotics, AntineoplasticCell Line, TumorDogsDoxorubicinHepatocyte Growth FactorHumansI-kappa B KinaseMaleMAP Kinase Kinase 3MAP Kinase Kinase 6MAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesNeoplasmsAntibiotics, AntineoplasticDoxorubicinHepatocyte Growth FactorHGF protein, humanI-kappa B KinaseMAP2K3 protein, humanMAP2K6 protein, humanMAP Kinase Kinase 3MAP Kinase Kinase 6MAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesNF-kappa Bp38 Mitogen-Activated Protein KinasesProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-metProto-Oncogene Proteins pp60(c-src)rac1 GTP-Binding ProteinRAC1 protein, human

Identifiers

PMID19047046
PMCPMC2658051
OpenAlexW2017890169

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.